Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age…
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ in Elderly and Updates to the Prescribing Information
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext…